SCHEMBL23218044

SCHEMBL23218044

CCOC(=O)Cc1ccc(OC(F)(F)F)cc1OCc1coc2ccc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
MTNR1A P48039 2/20 0.37
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ALOX5 P09917 2/20 0.34
PTGER4 P35408 1/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 1/20 0.34
ALDH2 P05091 1/20 0.34
PPARD Q03181 1/20 0.34
PSMB5 P28074 1/20 0.34
PTGER1 P34995 1/20 0.34
IDO1 P14902 1/20 0.33
WDR5 P61964 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852484 1.00 MAPT (0.38) MAPTMTNR1APOLBMEN1GAA
SCHEMBL23218045 0.89 MAPT (0.43) MAPTMTNR1APOLBMEN1KMT2A
SCHEMBL29852601 0.89 MAPT (0.43) MAPTMTNR1APOLBMEN1KMT2A
SCHEMBL29852948 0.87 PPARD (0.38) MAPTPOLBMEN1GAAKMT2A
SCHEMBL23218594 0.87 PPARD (0.38) MAPTPOLBMEN1GAAKMT2A
SCHEMBL23218975 0.86 MAPT (0.42) MAPTMTNR1APOLBMEN1GAA
SCHEMBL29852736 0.86 MAPT (0.45) MAPTMTNR1APOLBMEN1GAA
SCHEMBL23218720 0.86 MAPT (0.45) MAPTMTNR1APOLBMEN1GAA
SCHEMBL23218987 0.85 MAPT (0.40) MAPTMTNR1APOLBMEN1GAA
SCHEMBL29852463 0.85 MAPT (0.40) MAPTMTNR1APOLBMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAPT 4793/4885MTNR1A 3930/4885POLB 3530/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAPT 3561/4885MTNR1A 3848/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.